

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.170; Venous thromboembolism - rivaroxaban

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Bayer Schering (rivaroxaban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Anticoagulation Europe • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • British Hip Society • British Lung Foundation • Counsel and Care • Different Strokes • Equalities National Council • Heart Care Partnership UK • HEART UK • Lifeblood: The Thrombosis Charity • Muslim Council of Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Anticoagulation Specialist Association • Association of British Neurologists • Association of Surgeons of Great Britain and Ireland • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly • British Association for Surgery of the Knee • British Association of Stroke Physicians 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Archimedes Pharma (bemiparin sodium) • GlaxoSmithKline (fondaparinux sodium) • Leo Laboratories (tinzaparin sodium) • Pfizer Ltd (dalteparin sodium) • Sanofi-Aventis Ltd (enoxaparin sodium) • Valeant Pharmaceuticals Ltd (reviparin sodium) • Boehringer Ingelheim Ltd (dabigatran etexilate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists' (ATT) Collaboration • British Society for Cardiovascular Research

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Cardiovascular Society • British Cardiovascular Intervention Society • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Lung Foundation • British Orthopaedic Association • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • British Vein Institute • Clinical Leaders of Thrombosis (CLOT) • College of Emergency Medicine • Coronary Prevention Group • National Association of Primary Care • National Heart Forum (UK) • Primary Care Cardiovascular Society • Primary Care Neurology Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Physicians (Cardiology Committee & Intercollegiate Stroke Working Party) • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Royal Society of Medicine - Forum on Intellectual Disabilities • Royal Society of Medicine's Cardiothoracic Section • Society for Cardiological Science and Technology • Society for Vascular Technology • Society of British Neurological Surgeons • Society of Cardiothoracic Surgeons of Great Britain and Ireland • Society of Vascular Nurses • United Kingdom Clinical Pharmacy Association 	<ul style="list-style-type: none"> • British Stroke Research Group • Cochrane Heart Group • Cochrane Peripheral Vascular Disease Group • Cochrane Stroke Group • MRC Clinical Trials Unit • National Heart Research Fund • National Institute for Health Research • Oxford Stroke Prevention Research Unit • Research Institute for the Care of Older People • Thrombosis Research Institute • Safe Implementation of Treatments in Stroke(SITS) • UK Stroke Research Network • Wellcome Trust Cardiovascular Research Initiative <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre • National Collaborating Centre for Acute Care <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • None

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Camden • NHS Middlesbrough • Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues

PTO for definitions of consultees and commentators

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.